Ann: Broker Briefing Presentation, page-2

For those new to EMD, a little bit of 2021 research that should excite and help you understand why EMD-RX5 / EMD-RX7 below results are so "RedHot" And why IMO Jazz Pharmaceuticals will be all over EMD ATM


1st: EMD-RX5/ EMD-RX7 below results compare to (Epidyolex) are outstanding ( Massive Threat ) IMO



2nd: Jazz Pharmaceutical pays (US$ 7bill ++) for GW Pharmaceuticals, primarily to get access and control of Epidiolex
Jazz agreed to pony up $7.2 billion for cannabinoid hotshot GW Pharmaceuticals, whose epilepsy med Epidiolex could be on its way to blockbuster sales. Epidyolex (world’s only registered CBD medicine )

https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-completes-acquisition-gw-pharmaceuticals
https://www.fiercepharma.com/pharma/jazz-eyes-epilepsy-market-7-2b-buyout-cannabinoid-drugmaker-gw





3rd: Karen Smiths "New Role" Executive Director Emyria EMD




In short: Jazz paid heaps for control of the Epidiolex Drug (world’s only registered CBD medicine) EMD may just have something a fair bit better going of the above results !